Vycor Medical

Vycor Medical FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Vycor Medical (VYCO) as of Nov 4, 2026 is 25.81 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was -51.07 % — a change of -150.55% (higher).

FCF Conversion

25.81 %

YoY

-150.55%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Vycor Medical is 2025 25.81 % . FCF Conversion Rate (FCF/EBITDA) of Vycor Medical was 2024 -51.07 % . It decreases by -150.55% higher compared to the previous year.

The Vycor Medical FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
23.48 USD
Jan 1, 2019
7.40 USD
Jan 1, 2020
37.79 USD
Jan 1, 2021
3.90 USD
Jan 1, 2022
54.28 USD
Jan 1, 2023
-28.76 USD
Jan 1, 2024
-51.07 USD
Jan 1, 2025
25.81 USD
The Vycor Medical FCF Conversion history
YEARFCF ConversionYoY
25.81 %-150.55%
-51.07 %+77.56%
-28.76 %-152.99%
54.28 %+1,290.60%
3.90 %-89.67%
37.79 %+410.68%
7.40 %-68.48%
23.48 %-51.21%
48.12 %+43.41%
33.55 %-49.27%
66.14 %-5.41%
69.93 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Vycor Medical Stock analysis

What does Vycor Medical do? Vycor Medical Inc. is a US-based company specializing in the development and marketing of specialized medical devices and solutions. It was founded in 1989 in Boca Raton, Florida and is now headquartered in Westford, Massachusetts. The company offers a range of products in various medical fields, including instruments for neurosurgical procedures, devices for brain tumor removal, and treatment of chronic pain. Vycor Medical Inc. focuses on achieving a higher standard in medicine through innovative technologies, aiming to provide better patient care. One of their key products is the modular SDV™ system, designed to support neurosurgeons in brain surgeries. This transparent device and instrument system enhances visibility in the operating theater, enabling more accurate procedures. The system helps surgeons identify the target tissue and operate with greater precision, reducing complications during and after surgery. Another important product offered by Vycor Medical Inc. is the ViewSite™ Brain Access System, which is a carrier system for minimally invasive neurosurgical procedures. It ensures visibility during surgery and reduces the risk of complications. The system is designed to improve patient safety and enhance surgical outcomes. In 2016, Vycor Medical Inc. acquired NovaVision, a company specialized in rehabilitative therapy and visual rehabilitation. This acquisition allows Vycor to expand into the field of vision-related developmental disorders, aiming to provide innovative technologies for better treatment and improved quality of life for patients. The VBAS® Tissue Harvesting System is another product offered by the company, used for removing damaged skin tissue in various wounds. The VBAS® system improves visibility in the operating theater and helps reduce complications and pain for the patient. In addition to building a strong portfolio of medical instruments and solutions, Vycor Medical Inc. is actively involved in developing technologies for future medical applications. An example is the Gen3 Glass technology, which enhances contrast perception and reduces glare from operating room lights. The company also offers products such as protective eyewear for physicians. Overall, Vycor Medical Inc. has a successful history in developing and marketing specialized medical devices and solutions. They have set industry standards with innovative products like the SDV™ system and the ViewSite™ Brain Access System. Collaboration with healthcare professionals and experts is crucial for continuous product development and market growth. Vycor Medical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vycor Medical stock

FCF Conversion Rate (FCF/EBITDA) of Vycor Medical is 25.81 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Vycor Medical changed from -51.07 % to 25.81 %, representing a -150.55% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Vycor Medical since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Vycor Medical with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Vycor Medical

All Key Metrics — Vycor Medical